Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)

Cocaine Abuse Clinical Trial

— CATALYST  

Official title:

A Single-Blind, Randomized Study Comparing The Efficacy And Safety Of A Single Dose Of TNX-1300 To Placebo With Usual Care For The Treatment Of Signs And Symptoms Of Acute Cocaine Intoxication In Emergency Department Subjects (CATALYST Study)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06045793
• Other study ID #: TNX-CE-CI202
• Secondary ID: 5U01DA056245
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: December 11, 2023
• Est. completion date: June 4, 2024

Study information

• Verified date: November 2023
• Source: Tonix Pharmaceuticals, Inc.
• Contact: Sr. Manager, Clinical Programs
• Phone: 203-482-3938
• Email: Megha.Tevar[@]tonixpharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 2 single-blind, randomized, multicenter study to compare the efficacy and safety of a single dose of TNX-1300 to placebo with usual care in patients with acute cocaine intoxication within the emergency department setting.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: June 4, 2024
• Est. primary completion date: June 4, 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Subject is male (sex assigned at birth).

• Subject is 18-64 years of age.

• Subject has the capacity to provide voluntary written informed consent. In cases in which the investigator is unclear if the subject has the capacity to consent, a determination regarding capacity must be made by a psychiatrist trained in assessment of capacity to consent to research in order for the subject to be eligible.

• At Screening, subject presents with cardiac symptoms while intoxicated with cocaine, inclusive of elevated systolic and diastolic BP, as defined below, with or without behavioral symptoms:

• Systolic BP >140 mmHg

• Diastolic BP >90 mmHg Note: subjects with a QT interval corrected for heart rate (QTc) >500 msec may be eligible for study participation, based on investigator judgment.

• At Screening and Baseline assessments, subject must have a SIS total score of =4 and a score >1 on at least one of the 2 BP items (systolic and diastolic BP).

• At Baseline, subject has a CGI-S score =3.

• Subject has a positive urine drug screen test at Pre-screening to confirm cocaine use and detect polysubstance abuse (subject may test positive for cannabinoids and/or opioids and remain eligible; subject may test positive for alcohol by breathalyzer and remain eligible).

• Subject is a suitable candidate for investigational treatment based on the opinion of the investigator.

Exclusion Criteria:

• Subject who has been admitted to the ED involuntarily.

• Subject who participated in this clinical study previously.

• Subject has a score of 3 on the systolic and/or diastolic BP SIS components, a "mental state" or "orientation" SIS component score of =2, or an "orientation" SIS component score of =1 and the subject is not oriented to either person or place.

• Subject who, at Screening, expresses C-SSRS suicidal ideation of Type 4 or 5 in the prior week or any C-SSRS suicidal behavior in the prior week.

• Subject tests positive for stimulant drugs of abuse other than cocaine, including methylphenidate, 3,4-methylenedioxymethamphetamine, methamphetamine, or other amphetamines at Screening.

• Subject has a clinically significant untreated cardiac condition, such as prior myocardial infarction, current ischemia or severe left ventricular hypertrophy assessed by ECG-based criteria, aortic dissection, ventricular fibrillation, Torsade de pointes, ventricular tachycardia, cardiomyopathy, pulmonary edema, cardiac arrest, significant conduction disturbance (e.g., greater than first degree heart block), QRS interval >120 msec, or severe or life-threatening hypertension. Untreated hypertension may be allowed if not considered severe or life-threatening. Note: hypertension will be considered severe or life-threatening if systolic BP is >200 mmHg and/or diastolic BP is >130 mmHg.

• Subject incurred or is likely to incur a myocardial infarction or other life-threatening severe event or has acute ECG changes indicative of acute coronary syndrome according to investigator judgment. Such changes may include new, transient, or dynamic ST-segment elevation, ST-depression, or significant Q waves. Based on investigator judgement, T-wave inversion and T-wave flattening may also be considered in the risk assessment for acute coronary syndrome.

• Subject has a heart rate =180 bpm, atrial fibrillation, greater than first degree heart block, or chest pain with ECG-based evidence of ischemia.

• Subject has a clinically significant or unstable medical illness, condition, or disorder that can compromise subject safety or adversely affect the evaluation of clinical outcome parameters.

• Subject has a clinical history of anaphylaxis, severe asthma, hypersensitivity, or angioedema.

• Subject requires physical restraints due to physiological and/or behavioral symptoms.

• Subject receives anti-hypertensive medication(s) in the ED prior to study enrollment.

• Participation in another investigational drug study (current or within 30 days of Screening) or previous participation in a study of TNX-1300.

Related Conditions & MeSH terms

• Cocaine Abuse
• Cocaine Use
• Cocaine-Related Disorders
• Poisoning

Intervention

Drug:
• TNX-1300 (Injection)
Patients will receive a single IV injection of TNX-1300.
• Placebo (Injection)
Patients will receive a single IV injection of placebo with usual care (UC).

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
Tonix Pharmaceuticals, Inc.	National Institute on Drug Abuse (NIDA), Premier

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in Systolic BP at 60 minutes after dosing, comparing TNX-1300 to placebo with UC	Patients will undergo a Systolic BP assessment at Baseline and at 60 minutes after dosing.	60 minutes after IV administration
Secondary	Change from Baseline in QT interval corrected for heart rate (QTc) at 15 minutes after dosing, comparing TNX-1300 to placebo with UC	Patients will undergo a 12-lead ECG at Baseline and at 15 minutes after dosing.	15 minutes after IV administration
Secondary	Change from Baseline in diastolic BP at 60 minutes after dosing, comparing TNX-1300 to placebo with UC	Patients will undergo a Diastolic BP assessment at Baseline and at 60 minutes after dosing	60 minutes after IV administration
Secondary	Change from Baseline in Stimulant Intoxication Scale (SIS) total score at 60 minutes after dosing, comparing TNX-1300 to placebo with UC	Patients will be assessed with the SIS for characterizing severity of cocaine intoxication at Baseline and at 60 minutes after dosing. The SIS has 6 items, each of which is scored on a range of 0-3 (4 items) or 0-4 (2 items). The SIS has a total score range of 0 to 20, with 0 being the lowest severity and 20 being the highest severity.	60 minutes after IV administration